The PMPRB has extended the deadline for comments on the revised draft Guidelines to August 4, 2020.
See here for further details on the change. Please also see our June 23, 2020 article for a summary of notable changes in the revised draft Guidelines.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada announces new Pharmaceutical and Life Sciences Sector Task Force
On March 18, 2026, the federal Minister of Health announced the creation of the Pharmaceutical and Life Sciences Sector Task Force, a joint initiative led by Health Canada and Innovation, Science and ...Read More -
Canada’s Drug Agency releases updated Procedures for Reimbursement Reviews & new data on Health Technology Assessment timelines
On April 30, 2026, Canada’s Drug Agency (CDA) published updated Procedures for Reimbursement Reviews, following completion of a public consultation earlier this year. The updated procedures will be ef...Read More -
PMPRB releases May NEWSLetter and Meds Pipeline Monitor
On May 12, 2026, the Patented Medicine Prices Review Board (PMPRB) released its May NEWSLetter. The NEWSletter provides updates on the implementation of the new Guidelines for PMPRB Staff, the consult...Read More
